Effect of donepezil on cognition in severe Alzheimer's disease: A pooled data analysis

Journal of Alzheimer's Disease

Volumn 21, Issue 3, 2010, Pages 843-851

  Cummings, Jeffrey ^a   Jones, Roy ^b   Wilkinson, David ^c   Lopez, Oscar ^d   Gauthier, Serge ^e   Waldemar, Gunhild ^f   Zhang, Richard ^g   Xu, Yikang ^g   Sun, Yijun ^h   Richardson, Sharon ^h   MacKell, Joan ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

^c MOORGREEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f Rigshospitalet   (Denmark)

^g PFIZER INC   (United States)

^h EISAI INC   (United States)

Author keywords

Alzheimer's disease; cognition; donepezil; functional outcome; global outcome; placebo controlled; pooled data analysis; severe Alzheimer's disease; Severe Impairment Battery

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 77957252878     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100078     Document Type: Article

References (35)

1. Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimer's Association web site. http://www.alz.org/national/documents/report alzfactsfigures2009.pdf. Accessed on September 16, 2009.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122. (Pubitemid 36975801)
3. Helmer C, Peres K, Letenneur L, Guttierez-Robledo LM, Ramaroson H, Barberger-Gateau P, Fabrigoule C, Orgogozo JM, Dartigues JF (2006) Dementia in subjects aged 75 years or over within the PAQUID cohort: Prevalence and burden by severity. Dement Geriatr Cogn Disord 22, 87-94. (Pubitemid 43909834)
4. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S (1998) Relation between severity of Alzheimer's disease and costs of caring. CMAJ 159, 457-465. (Pubitemid 28454314)
5. Smith GE, O'Brien PC, Ivnik RJ, Kokmen E, Tangalos EG (2001) Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology 57, 1467-1473. (Pubitemid 32995730)
6. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P (2003) Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 51, 737-744. (Pubitemid 36693421)
7. Hogan DB (2006) Donepezil for severe Alzheimer's disease. Lancet 367, 1031-1032.
8. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V (2004) Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63, 644-650. (Pubitemid 39100819)
9. National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). National Institute for Health and Clinical Excellence Web site. http://www.nice.org.uk/nicemedia/pdf/TA111Guidance AmendedAug09.pdf. Accessed on September 17, 2009.
10. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
11. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
12. Farlow M(2005) Moderate to severe Alzheimer disease: Definition and clinical relevance. Neurology 65 (6 Suppl 3), S1-S4. (Pubitemid 41362107)
13. Schmitt FA, Wichems CH (2006) A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry 8, 158-159.
14. Panisset M, Roudier M, Saxton J, Boller F (1994) Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 51, 41-45. (Pubitemid 24020169)
15. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S (2007) Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69, 459-469. (Pubitemid 47450281)
16. Feldman H, Gauthier S, Hecker J,Vellas B, Subbiah P, Whalen E (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57, 613-620. (Pubitemid 32782987)
17. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T (2008) Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 25, 399-407. (Pubitemid 351630073)
18. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, for the Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341. (Pubitemid 36384100)
19. Tariot PN, FarlowMR, GrossbergGT, Graham SM,McDonald S, Gergel I, for the Memantine Study Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291, 317-324. (Pubitemid 38101604)
20. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A (2006) Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 367, 1057-1065.
21. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ (1997) The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), S51-S56.
22. Wild KV, Kaye JA (1998) The rate of progression of Alzheimer's disease in the later stages: evidence from the Severe Impairment Battery. J Int Neuropsychol Soc 4, 512-516.
23. Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA (1996) Clinical evaluation of global change in Alzheimer's disease: Identifying consensus. J Geriatr Psychiatry Neurol 9, 176-180. (Pubitemid 27028868)
24. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), S33-S39.
25. Gelinas I, Gauthier L, McIntyre M, Gauthier S (1999) Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther 53, 471-481.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
27. American Psychiatric Association (1995) Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. DSM-IV. American Psychiatric Association Publishing, Arlington, V.A.
28. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6, 65-70.
29. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates, Hillsdale, N.J.
30. Cohen J (1992) A power primer. Psychol Bull 112, 155-159.
31. Leber P (1990) Guidelines for the clinical evaluation of antidementia drugs. First draft. US Food and Drug Administration, Rockville, M.D.
32. Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS (2008) Donepezil in patients with subcortical vascular cognitive impairment: A randomised double-blind trial in CADASIL. Lancet Neurol 7, 310-318.
33. Tekin S, Fairbanks LA, O'Connor S, Rosenberg S, Cummings JL (2001) Activities of daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 9, 81-86. (Pubitemid 32062077)
34. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frolich L, Hock C, Raivio M, Triau E, Vandewoude M, Wimo A, Came E, Van Baelen B, Hammond GL, Van Oene JC, Schwalen S (2009) Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol 8, 39-47.
35. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281, 1401-1406. (Pubitemid 29190218)